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Oxidative stress has long been implicated in the pathophysiology and progression of
Huntington’s disease (HD). Uric acid (UA) is a naturally occurring antioxidant that is
present in the brain and periphery. Growing evidence has implicated UA as a molecular
biomarker for several neurodegenerative diseases, most notably Parkinson’s disease
(PD). In this study, we investigated UA levels in clinical samples from HD patients and
normal controls (NCs) and assessed potential relationships between UA levels and
disease and clinical data. UA levels were measured in plasma (n = 107) and saliva
(n = 178) samples from premanifest (pre-HD) and manifest HD patients and control
subjects. Gender effects of UA levels were observed in both biofluids, with male patients
showing higher UA levels compared to female patients. Comparisons of UA levels across
diagnostic groups, separated by gender, revealed that both plasma and salivary UA
levels were significantly lower in female pre-HD and manifest HD patients compared to
NCs. Salivary levels of UA were also significantly lower in male manifest HD patients
versus controls, but not in plasma. Correlations of peripheral UA levels to clinical data
also showed differences according to gender. In male HD patients, both plasma and
salivary UA levels were significantly negatively correlated with total functional capacity
(TFC), while positive correlations were observed with total motor score (TMS). Female
HD patients showed a significant positive correlation between plasma UA levels and
TMS, while salivary UA levels from female patients were significantly correlated to
disease burden. Finally, in a separate cohort, we show that UA levels are decreased
in postmortem prefrontal cortical samples (n = 20) from HD subjects compared to
matched controls. These findings suggest that decreased levels of UA in the brains of
HD patients can be reflected in peripheral fluids, with salivary measures of UA particularly
offering significant promise as a potentially relevant, non-invasive biomarker of disease
symptoms and burden. Our findings further highlight the impact of sexual dimorphism
in HD pathophysiology.
Keywords: neurodegenerative, biomarker, peripheral, brain, blood, saliva, biofluid
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INTRODUCTION
Huntington’s disease (HD) is an inherited, progressive
neurodegenerative disorder caused by a CAG repeat expansion in
the 5′ coding region of the Huntington (HTT) gene (Huntington
Disease Collaborative Research Group, 1993). Despite enormous
progress in our understanding of this disease, the mechanisms
connecting mutant huntingtin (Htt) protein with cell death
and pathological symptoms remain unclear. Oxidative damage,
mitochondrial dysfunction, and impairment in the electron
transport chain have been suggested to have important roles in
the degenerative process in HD (Browne et al., 1997; Trushina
and McMurray, 2007; Franco-Iborra et al., 2018; Zheng et al.,
2018). Specifically, past studies have demonstrated enhanced
oxidative stress and oxidative DNA damage in peripheral blood
from HD patients (Chen et al., 2007), in cultured fibroblasts
from HD patients, in HD mouse models (Goula et al., 2009), and
in striatal cells derived from HD knock-in mice (Li et al., 2010;
Ribeiro et al., 2012). Oxidative damage is not considered to be
substantial in the early stages of HD, but rather is proposed to be
a major contributor to pathology as the disease progresses (Johri
and Beal, 2012). HD symptoms typically appear between the
ages of 35 and 55, although juvenile forms of the disease exist,
which present before the age of 20 (van Dijk et al., 1986), and
the disease progresses over 10–20 years from a presymptomatic
state to complete disability and death. The age of onset for HD
varies inversely with the length of the disease-causing CAG
repeat mutation, with the threshold being between 36 and 39
triplet repeats (Andresen et al., 2007). However, the age of onset
and its progression vary considerable among patients, even
among patients with identical CAG repeat lengths (Andrew et al.,
1993; Wexler et al., 2004; Andresen et al., 2007), warranting the
need for biomarkers that might help predict onset. In addition,
gender has emerged as another factor that can affect disease
outcomes in HD, with women showing worse symptoms and a
faster rate of progression (Dorner et al., 2007; Zielonka et al.,
2013). In fact, there are several gender-related differences that
have been reported in other neurodegenerative diseases as well,
which have enhanced our current understanding of the impact of
sexual dimorphism in neurological diseases and the implications
for preventive and therapeutic outcomes (Zagni et al., 2016;
Ullah et al., 2019).
Uric acid (UA), an endogenous compound that is formed as
the end-product of purine metabolism, is a powerful antioxidant
in the CNS and periphery. In fact, UA is the most abundant
natural antioxidant in human blood. Although imbalanced UA
levels have a long-standing association with medical conditions
such as gout, UA also affects the central nervous system and
has been specifically been linked to neurological conditions
(Bowman et al., 2010; Fang et al., 2013). With respect to
neurodegenerative diseases, the interest in UA was initially
sparked by evidence of oxidative damage in another movement
disorder, Parkinson’s disease (PD). Previous work in PD has
demonstrated low levels of UA in postmortem substantia nigra
(Church and Ward, 1994; McFarland et al., 2013), as well as
in blood from PD patients (Davis et al., 1996; Schlesinger and
Schlesinger, 2008). Since these early observations, accumulating
epidemiological studies, laboratory data, preclinical models, and
early clinical trial results have provided substantial support for
a neuroprotective role for UA and its potential as a disease
biomarker for PD (Constantinescu and Zetterberg, 2011; Chen
et al., 2012; Crotty et al., 2017). In particular, UA has been
suggested as a promising biomarker of reduced risk and milder
progression in PD (Schlesinger and Schlesinger, 2008; Paganoni
and Schwarzschild, 2017; Wen et al., 2017).
Because oxidative stress represents a shared pathological
mechanism, not only between PD and HD but also across
several neurodegenerative diseases, we hypothesized that UA
could also serve as a potentially relevant biomarker in HD.
Hence, in this study, we measured UA levels in peripheral fluids
and postmortem brain samples from HD patients and assessed
their potential relationships with disease and clinical data. We
include saliva in this study as a non-invasive alternative to
blood, and a biofluid that has the potential to expand biomarker
measurements in diverse settings.
MATERIALS AND METHODS
Human Subjects
This study was approved by the University of California, San
Diego (UCSD) Institutional Review Board in accordance with
the requirements of the Code of Federal Regulations on the
Protection of Human Subjects. Informed consent from all
subjects was obtained before their participation in accordance
with the Declaration of Helsinki. Patients were recruited from the
UCSD HDSA Center of Excellence. HD patient criteria included
a definitive diagnosis of HD with family history and an expanded
trinucleotide CAG repeat of 40 or more. Normal controls (NCs)
had no reported history of neurological conditions, psychiatric
disorders, or gout, and no use of psychoactive substances or
medications. Demographic information was collected at the time
of saliva collection, including sex, age, CAG repeat length, and age
of onset. This information is provided in Table 1. Patients were
assessed for cognitive and motor function using the Mini-Mental
State Examination (MMSE; score range, 0–30) (Gluhm et al.,
2013), the Unified Huntington’s Disease Rating Scale (UHDRS)
total motor score (TMS; range, 0–124), and total functional
capacity (TFC; range, 0–13). Overall genetic or disease burden
was assessed using the disease burden score (DBS). These data
are summarized in Supplementary Table S1.
Plasma Collection
Blood from consenting HD patients and controls was drawn by
venipuncture into 2 ml lavender/ethylenediaminetetraacetic acid
(EDTA) tubes. EDTA/whole blood was mixed well by inversion
and spun at 900 × g for 15 min. The top plasma layer was
transferred into 4 × 1 ml aliquots and snap frozen and stored at
−80◦C. All subjects who provided a plasma sample also provided
a saliva sample.
Saliva Collection
All donors were asked to refrain from smoking, eating, drinking,
or oral hygiene procedures for at least 1 h before sample
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TABLE 1 | Summary of subjects used for these studies.
HD Pre-HD NC Total no.
Plasma
Number of patients 38 31 38 107
Female/male 22:16 18:13 18:20 58:49
Average age (years) 59.5 ± 13.1 43.7 ± 13.8 59.9 ± 14.3
Average CAG repeat 42.7 ± 2.8 41.3 ± 1.9 NA
Saliva
Number of patients 45 49 84 178
Female/male 29:16 26:23 41:43 96:82
Average age (years) 56.5 ± 13.4 44.8 ± 12.2 52.9 ± 16.02
Average CAG repeat 43.5 ± 2.8 41.0 ± 1.7 NA
Postmortem brain
Number of subjects 10 10 20
Female/male 3:7 3:7 6:14
Average age (years) 59.6 ± 4.33 60.0 ± 4.32
Average PMI 13.5 ± 5.08 16.8 ± 9.1
PMI, postmortem interval; HD, Huntington’s disease; Pre-HD, premanifest; NC,
normal controls.
collection and then rinsed their mouth thoroughly with water 15–
20 min before sample collection. Saliva samples were collected
between 10:00 AM and 4 PM using the passive drool method
according to previously established protocols (Granger et al.,
2012). Roughly 2–3 ml of unstimulated whole saliva was
obtained. Besides the patients who provided a plasma sample,
an additional group of patients provided a saliva-only sample.
Samples were immediately frozen at −20◦C at the time of
collection and then stored at −80◦C. At the time of use,
saliva samples were thawed and centrifuged at 10,000 × g for
10 min at 4◦C to remove insoluble material and cellular debris.
Supernatants were collected and used for all assays.
Postmortem Brain Samples
Prefrontal cortical tissue was obtained postmortem from subjects
with HD cases and age-matched NCs with no history of
psychiatric illness. Tissues were obtained from the National
Institutes of Health (NIH) NeuroBioBank1. All HD cases
showed a moderately to severely atrophied cortical tissue with
pathological grades 2–4. Exact CAG repeat numbers were not
available. Details such as Vonsattel grading, age, gender, and
postmortem delay can be found in Table 1. Frozen tissue
samples (∼1 g) were homogenized in lysis buffer and then
centrifuged at 10,000 × g at 4◦C for 20 min. Supernatant
fractions were used for UA assays below. Total protein levels in
each sample were quantified by the bicinchoninic acid (BCA)
protein assay (Abcam). Brain samples were obtained from a
separate cohort of subjects than those providing plasma and/or
saliva samples above.
UA Measurements
Uric acid levels in all samples were measured using a
commercially available colorimetric enzymatic reaction kit
1https://neurobiobank.nih.gov/
(Catalog No. 1-3802, Salimetrics, CA, United States). The amount
of UA in the sample was assessed by measuring the production of
red chromogen during an enzymatic reaction process. All assays
were performed in duplicate by operators blinded to the clinical
state of the participant. The assay used 10 µl of sample per well
and had a range of sensitivity from 0.78 to 25 mg/dl.
Statistics
The distribution of the data values in brain samples and each
peripheral fluid was tested for normality using the Kolmogorov–
Smirnov normality test to determine whether parametric or
non-parametric tests would be used for correlation variables.
Outlier values were determined using either the Grubb’s test for
sex and age comparisons or the Iglewicz and Hoaglin’s robust
test for multiple outliers (two-sided test; z = 3.5) for diagnostic
comparisons, resulting in the removal of two datapoints for the
plasma samples and four datapoints for the saliva samples. A one-
way analysis of covariance (ANCOVA) was used to determine
if differences in diagnostic groups were associated with age or
gender. Group differences separated by sex were determined by
one-way ANOVA, followed by Bonferroni or Tukey’s multiple
comparison test. Linear regression analysis (Pearson or Spearman
correlation) was used to compare UA levels against disease
and clinical variables. Differences between sex and postmortem
interval (brain samples only) were determined using Student’s
t-test (unpaired; two-tailed). Statistical analyses were performed
using JASP STATs and Prism.
RESULTS
Plasma UA in HD Patients
We measured UA concentrations in plasma from patients with
manifest HD (n = 38), premanifest HD (designated “pre-
HD”) (n = 31), and healthy NC individuals with no history
of neurological or psychiatric disorders (n = 38) (Table 1).
There was no significant difference in plasma UA levels between
genders in control subjects, although levels were significantly
higher in male compared to female patients in pre-HD and
HD subjects (Figure 1A) consistent with previous studies
(Andreadou et al., 2009; Kivity et al., 2013; Riis et al., 2018;
Yang et al., 2019). Gender ratios across the three groups of
subjects were not significantly different. The pre-HD group was
statistically significantly younger than both the controls and
manifest HD groups (ANOVA p < 0.001); however, when both
age and gender were considered as covariates in determining
the difference between diagnostic groups using ANCOVA, the
age effect was not significant (p < 0.193), with the gender effect
remaining (p < 0.006). Accordingly, linear correlation revealed
no significant effects of age on UA levels (Figure 1B).
Owing to the significant gender effect, we compared UA
levels across diagnostic groups in male and female HD patients
separately. Using ANOVA, we found that female subjects showed
significantly lower levels of UA in both pre-HD and manifest HD
patients versus NCs (ANOVA p < 0.014; p < 0.05 for NC vs.
pre-HD and NC vs. HD; Figure 2A). Similar decreases were not
observed in male patients (ANOVA p< 0.469; Figure 2B).
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FIGURE 1 | Gender and age effects of uric acid (UA) in plasma from Huntington’s disease (HD) patients and normal controls (NC). (A) Significant differences in
gender were determined by Student’s t-test, unpaired; two-tailed; p < 0.0001. The HD patients include pre-HD (PM) and manifest HD patients. (B) Plasma UA levels
were not significantly associated with age in any group.
FIGURE 2 | Changes in plasma uric acid (UA) levels by gender and diagnostic group. UA levels were measured in premanifest [pre-Huntington’s disease (PM),
manifest HD and normal control (NC) subjects in females (A) and males (B). Significant differences among diagnostic groups were determined using one-way
ANOVA, followed by Bonferroni posttest to compare all groups; p < 0.05. Bars reflect the mean uric acid levels ± SD.
We next correlated UA levels with clinical data, keeping the
gender distinction. In male manifest HD patients, plasma UA
levels were significantly negatively correlated with TFC (Pearson
r = −0.600; p = 0.014) and positively correlated with TMS from
the UHDRS (Pearson r = 0.644; p = 0.007) (Table 2). In female
manifest HD patients, plasma UA levels were positively correlated
with TMS (Pearson r = 0.656; p = 0.005), similar to the effect
observed in male patients (Table 2). No significant correlations
were detected between plasma UA levels and clinical or disease
metrics in pre-HD patients of either gender.
Measures of UA in Saliva From HD
Patients
We next assessed UA levels in saliva from pre-HD patients
(N = 49), HD patients (n = 45), and control subjects (n = 84)
(Table 1). We found that salivary UA levels were significantly
higher in male compared to female patients in both cohorts
(Figure 3A), consistent with previous studies on saliva (Riis
et al., 2018). Similar to the plasma cohort, the pre-HD patients
were statistically significantly younger than both the controls and
manifest HD groups (ANOVA p< 0.0001); however, age was not
considered a significant covariate in determining the difference
between diagnostic groups using ANCOVA (p < 0.350).
Accordingly, linear correlation revealed no significant effects of
age on salivary UA levels in any diagnostic group (Figure 3B).
Owing to the significant gender effect, we compared salivary
UA levels across diagnostic groups in male and female HD
patients separately. We found that salivary UA levels were
significantly lower in female pre-HD and HD patients compared
to NCs, with nearly a 40% reduction in UA concentration
detected in HD patients (ANOVA p < 0.0048; p < 0.05 for NC
vs. pre-HD and NC vs. HD, Figure 4A). In male patients, UA
levels were significantly lower in manifest HD patients compared
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TABLE 2 | Correlations between plasma uric acid and clinical and disease data in female and male HD patients.
Female Male
Premanifest HD Manifest HD Premanifest HD Manifest HD
Pearson/
Spearman
rho value
p-Value Pearson/
Spearman
rho value
p-Value Pearson/
Spearman
rho value
p-Value Pearson/
Spearman
rho value
p-Value
DBS 0.439 0.077 −0.012 0.944 0.306 0.310 0.171 0.526
TFC 0.274 0.071 −0.133 0.426 −0.207 0.498 −0.600 0.014
MMSE 0.231 0.959 −0.093 0.579 −0.152 0.620 −0.179 0.508
TMS 0.075 0.690 0.656 0.005 0.029 0.926 0.644 0.007
CAG repeat no. 0.533 0.057 −0.087 0.621 0.380 0.353 −0.064 0.820
Age of Onset NA NA 0.296 0.180 NA NA 0.171 0.527
Disease duration NA NA 0.140 0.402 NA NA 0.100 0.714
Values in bold denote statistically significant correlations. DBS, disease burden score; TFC, total functional capacity score; MMSE, Mini-Mental State Exam; TMS, total
motor symptom score.
to controls and pre-HD subjects (ANOVA p < 0.0001; p < 0.001
for NC vs. pre-HD and NC vs. HD, respectively, Figure 4B).
Comparing to clinical data, we found that salivary UA
levels in male HD patients showed the same effects as plasma
UA levels, being significantly negatively correlated with TFC
(Pearson r = −0.617; p = 0.012) and positively correlated with
TMS (Pearson r = 0.627; p = 0.009) (Table 3). In female HD
patients, salivary UA levels were significantly correlated with
DBS (Pearson r = −0.434; p = 0.009), CAG repeat length
(Spearman r = −0.397; p = 0.018). No significant correlations
were observed between salivary UA levels and any clinical or
disease metric in pre-HD patients of either gender, consistent
with the findings from blood.
Plasma UA Levels Versus Salivary UA
Levels
All subjects who donated a plasma sample also provided a saliva
sample; hence, we could directly compare levels of UA in both
peripheral fluids in the same individuals. In both male and
female normal subjects, plasma levels of UA were higher than
those found in saliva (Student’s t-test; p < 0.0001), consistent
with previous studies (Riis et al., 2018). We next examined
whether levels of UA in blood correlated with those detected in
saliva in all pre-HD and HD patients and found a significant
correlation between UA levels in plasma versus saliva (Spearman
r = 0.495; p < 0.0001) (Figure 5), suggesting that salivary UA
levels originate, at least in part, from blood sources.
Uric Acid Levels in HD Postmortem Brain
In a separate study, we measured UA levels in prefrontal cortex
obtained postmortem from 10 HD patients and 10 healthy
age-matched NCs. The demographic data for these subjects
are shown in Table 1. There were no significant differences
in mean age, postmortem interval, or sex ratios between the
HD and control groups. UA measurements were normalized by
total protein levels in each sample to account for differences
in starting amounts of tissue. Regression analyses revealed no
significant correlations between UA and age or postmortem
interval in either group (Supplementary Table S2), although
a trend toward a significant correlation with age was observed
in the control group (Supplementary Table S2). Comparing
between diagnostic groups revealed a significant decrease in UA
levels in prefrontal cortex from HD patients compared to NCs
(16.8 ± 5.6 vs. 34.3 ± 21.4 ng/mg total protein) (Figure 6).
This difference was not affected by sex or age as determined by
ANCOVA (p = 0.270 and p = 0.337 for sex and age, respectively).
DISCUSSION
Despite accumulating evidence for enhanced oxidative stress
and oxidative damage in HD (Chen et al., 2007; Goula et al.,
2009; Li et al., 2010; Ribeiro et al., 2012), the major pathways
and the sequence of oxidative stress-associated events in HD
pathophysiology are poorly understood. Nonetheless, as an
endogenous antioxidant, UA represents a potentially relevant
biomarker for studies in HD. In this study, we show that
UA levels are significantly lower in the plasma and saliva of
HD patients compared to healthy controls. This decrease in
UA was also detected in postmortem brain samples from HD
patients, which is consistent with a previous study that found
lower UA levels in postmortem frontal lobe and striatum from
HD subjects using high-resolution mass spectrometry (Graham
et al., 2016). However, our findings further demonstrate that
decreased UA concentrations are also detected in peripheral
fluids, including the non-invasive biofluid, saliva. This could
possibly reflect a reduced antioxidant capacity in HD that is
manifested throughout the body.
Importantly, our results highlight important gender
differences in UA levels and the utility for UA to serve as a
potential disease biomarker. There are a number of gender-
related differences that have been reported in neurodegenerative
diseases (Ullah et al., 2019), which have made it necessary
to incorporate sex as a biological factor in experimental and
clinical studies. Importantly, such studies have enhanced the
current understanding of the impact of sexual dimorphism in
neurological diseases (Zagni et al., 2016; Ullah et al., 2019). In
our studies, we first found that UA levels were higher in male
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FIGURE 3 | Gender and age effects of uric acid (UA) in saliva from Huntington’s disease (HD) patients and normal controls (NC). (A) UA levels were significantly
higher in males compared to females in both NC and HD groups. The HD group also included pre-HD patients (PM). Significant differences were determined by
Student’s t-test, unpaired; two-tailed; p = 0.05; p = 0.003. (B) No significant effects of age on salivary UA levels were observed in any group.
FIGURE 4 | Alterations in salivary uric acid (UA) levels according to diagnostic group in females (A) and males (B). Uric acid levels are shown according to diagnostic
group, premanifest [pre-Huntington’s disease (PM), manifest HD (HD), and normal controls (NC). Significant differences among diagnostic groups were determined
using one-way ANOVA, followed by Bonferroni posttest to compare all groups: p < 0.05, p < 0.001, p < 0.0001, as shown. Bars reflect the mean uric acid
levels ± SD.
TABLE 3 | Correlations between salivary uric acid and clinical and disease data in female and male HD patients.
Females Males
Premanifest HD Manifest HD Premanifest HD Manifest HD
Pearson/
Spearman
rho value
p-Value Pearson/
Spearman
rho value
p-Value Pearson/
Spearman
rho value
p-Value Pearson/
Spearman
rho value
p-Value
DBS 0.257 0.186 −0.435 0.009 −0.020 0.943 0.444 0.129
TFC 0.187 0.330 0.035 0.844 0.173 0.521 −0.617 0.012
MMSE −0.234 0.221 0.209 0.236 −0.412 0.113 −0.339 0.257
TMS 0.157 0.418 −0.090 0.605 0.019 0.945 0.627 0.009
CAG repeat # 0.052 0.848 −0.397 0.018 −0.004 0.990 0.538 0.058
Age of Onset NA NA 0.186 0.285 NA NA −0.379 0.202
Disease duration NA NA 0.104 0.553 NA NA −0.111 0.718
DBS, disease burden score; TFC, total functional capacity score. MMSE, mini-mental state exam; TMS, total motor symptom score. Values shown in bold denote
statistically significant correlations.
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FIGURE 5 | Correlation between plasma and salivary levels of uric acid (UA).
The correlation between plasma and salivary levels of UA was determined
using Spearman correlation analysis. Pearson r = 0.495; p < 0.0001. The
same subjects provided paired saliva and plasma samples; however, for some
subjects, the saliva and plasma were collected on different days spaced up to
a week apart.
FIGURE 6 | Uric acid (UA) levels in postmortem prefrontal cortex from
Huntington’s disease (HD) subjects and matched controls. UA levels,
corrected for total protein, were measured in prefrontal cortical samples from
n = 10 HD patients and n = 10 matched normal controls (NC). Data points
reflect mean + SD. Difference in UA concentrations in HD versus normal
controls was determined using Student’s t-test (unpaired, two-tailed),
p = 0.022.
compared to female patients in all of the biospecimens we tested.
This is consistent with several past studies, where it has been
shown that men have higher levels of UA than women in blood
and saliva (Andreadou et al., 2009; Kivity et al., 2013; Riis et al.,
2018; Yang et al., 2019). The reason for this difference is not clear,
but possible explanations include alcohol consumption, which is
higher in men, and the influence of estrogens to lower UA (Jung
et al., 2018; Yang et al., 2019). Next, we found gender differences
in the ability of UA to distinguish diagnostic groups. In female
patients, plasma and salivary levels of UA were significantly
lower in both pre-HD and manifest HD patients, while in male
patients, UA concentrations were only lower in the saliva of
manifest HD patients. The higher levels found in the saliva from
male patients, in general, might mask a potential disease effect
of UA tested here.
Or there may be a true difference in the role of UA in HD
pathology in male vs. female patients. For example, a study
examining the relationship between gender and progression of
the disease showed that gender played a significant role in
the neuropathological changes and phenotypical expression in
HD (Dorner et al., 2007). Another study also found a gender
influence in disease severity with women displaying poorer
motor and functional UHDRS scores (Zielonka et al., 2013).
Hence, it is possible that disease-propagating mechanisms are
different in men and women, and our studies would suggest an
involvement of oxidative stress in these mechanisms. We found
that in male HD patients, both plasma and salivary UA levels
were significantly positively correlated with TMS and negatively
correlated with TFC. The direction of these correlations might
appear at odds with the decreased levels of UA detected in HD
patients compared to NCs, which would suggest that a reduced
antioxidant capacity is detrimental. However, within the HD
population, our results would suggest that higher UA levels are
more damaging. It is known that too much UA can have negative
consequences, such as proinflammatory effects, associated with
increased cytokines (Fang et al., 2013). This is consistent with
the literature demonstrating increase proinflammatory markers,
including interleukin 6 and 1B, in the plasma of premanifest HD
patients and in presymptomatic HD mice (Dalrymple et al., 2007;
Chang et al., 2015; Politis et al., 2015).
Our findings in plasma are consistent with past literature in
other neurodegenerative disorders, where lower blood and brain
levels of UA have been reported in PD, ALS, and Alzheimer’s
disease patients (Church and Ward, 1994; Constantinescu and
Zetterberg, 2011; Chen et al., 2012; Crotty et al., 2017). In PD,
correlations were observed between higher serum levels of UA
and not only a lower risk of developing the disease but also a
slower rate of disease progression (Schlesinger and Schlesinger,
2008; Paganoni and Schwarzschild, 2017; Wen et al., 2017).
Interestingly, studies in PD have also reported differences in men
and women, with one study showing correlations between serum
UA levels and disease duration in patients with PD only in men
(Andreadou et al., 2009). Other studies have implicated serum
UA as a biomarker for coronary artery disease only in women
(Sun et al., 2019).
Our findings in saliva are novel. Biomarker research in saliva
has grown over the past few years (Corey-Bloom et al., 2018),
largely due to its non-invasive nature and ease of collection in
any setting. Here, we have shown that the UA data in saliva
mimic several features of plasma and that levels of salivary
UA are correlated with those found in plasma. This would
suggest that at least some of the UA present in saliva originates
from blood sources. However, salivary levels of UA could also
arise from leukocytes and buccal cells present in saliva, or
the salivary glands themselves, which are innervated by the
glossopharyngeal and facial nerves, suggesting potential neural
release of UA in saliva.
Potential confounds of our study could be the effects of diet
and stress, which could differ between patients and controls.
It is known that UA levels can vary according to diet (Zgaga
et al., 2012; Towiwat and Li, 2015), and stress and strenuous
exercise have been shown to elevate UA (Gonzalez et al., 2008).
Frontiers in Neuroscience | www.frontiersin.org 7 March 2020 | Volume 14 | Article 73
fnins-14-00073 March 3, 2020 Time: 18:24 # 8
Corey-Bloom et al. Uric Acid in Huntington’s Disease
However, previous studies have demonstrated that, while there is
some “state specific” variation in salivary UA levels, the majority
of the variance in salivary UA can be attributable to a “trait-like”
stable component of the variance (Riis et al., 2018). In addition,
the potential effects of medications should be considered in future
studies on saliva. For example, some medications can affect UA
levels (Caspi et al., 2000) or can cause xerostomia, reducing
salivary output.
The utility of salivary measures to reveal information about
HD disease features is especially exciting, given the non-invasive
nature of saliva collection, although this is a new field with respect
to neurological disorders. UA could be an important potential
biomarker of disease symptoms and genetic burden, albeit in a
gender-specific manner. The fact that the decrease in UA levels in
the CNS can be revealed in peripheral fluids is especially exciting
and should encourage future studies investigating UA levels in
cerebrospinal fluid (CSF) from HD patients.
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